Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection

New Microbiologica

Volumn 35, Issue 3, 2012, Pages 335-340

  Figura, Natale ^a   Moretti, Elena ^a   Vaglio, L ^a   Langone, F ^a   Vernillo, Remo ^b   Vindigni, Carla ^c   Giordano, Nicola ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b Section of Surgical Oncology   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

CagA; Coccoid forms; Eradication treatment; H. pylori infection; Peptic ulcer

Indexed keywords

AMOXICILLIN; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CAGA PROTEIN, HELICOBACTER PYLORI; METRONIDAZOLE; OMEPRAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BIOPSY; BLOOD; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PEPTIC ULCER; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BIOPSY; DRUG RESISTANCE, BACTERIAL; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER; TREATMENT OUTCOME;

COCCOIDEA; HELICOBACTER PYLORI;

EID: 84864543674     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. ANDERSEN L. P., RASMUSSEN L. (2009). Helicobacter pylori coccoid forms and biofilm formation. FEMS Immunol. Med. Microbiol. 56, 112-115.
2. BROUTET N., TCHAMGOUE S., PEREIRA E., LAMOULIATTE H., SALAMON R., MÉGRAUD F. (2003). Risk factors for failure of Helicobacter pylori therapy results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Ther. 17, 99-109. (Pubitemid 36140439)
3. CENSINI S., LANGE C., XIANG Z., CRABTREE J. E., GHIARA P., BORODOVSKY M., RAPPUOLI R., COVACCI A. (1996). cag, a pathogenicity island of Helicobacter pylori, encodes type I specific and disease-associated virulence factors. Proc. Natl. Acad. Sci. USA. 93, 14648-14653.
4. DIXON M. F., GENTA R. M., YARDLEY J. H., CORREA P. (1996). Classification and grading of gastritis. The updated Sydney System. International Workshop on the histopathology of gastritis, Houston 1994. Am. J. Surg. Pathol. 20, 1161-1181.
5. FURUTA T., EL-OMAR E. M., XIAO F., SHIRAI N., TAKASHIMA M., SUGIMURA H. (2002). Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology. 123, 92-105. (Pubitemid 34747529)
6. GATTA L., VAKIL N., LEANDRO G., DI MARIO F., VAIRA D. (2009). Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am. J. Gastroenterol. 104, 3069-3079.
7. GEORGOPOULOS S. D., LADAS S. D., KARATAPANIS S., MENTIS A., SPILIADI C., ARTIKIS V., RAPTIS S. A. (2000). Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. Dig. Dis. Sci. 45, 63-67. (Pubitemid 30111689)
8. GRANDE R., DI GIULIO M., DI CAMPLI E., DI BARTOLOMEO S., CELLINI L. (2010) A model of Helicobacter pylori persistence in a case of gastric cancer. New Microbiol. 33, 343-349.
9. GRAYSON M. L., ELIOPOULOS G. M., FERRARO M. J., MOELLERING R. C. JR. (1989). Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 8, 888-889. (Pubitemid 19265874)
10. HUANG J.-Q., ZHENG G.-F., HUNT R. H., WONG W.-M., LAM S.-K., KARLBERG J., WONG B. C.-Y. (2005). Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylorieradication treatments from those with peptic ulcer disease? A systematic review. World J. Gastroenterol. 11, 2726-2732. (Pubitemid 40704237)
11. MAKIPOUR K., FRIEDENBERG F. K. (2011). The potential role of N-Acetylcysteine for the treatment of Helicobacter pylori. J. Clin. Gastroenterol. 45, 841-843.
12. RIMBARA E., FISCHBACH L. A., GRAHAM D. Y. (2011). Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 8, 79-88.
13. RUDI J., REUTHER S., SIEG A., HOERNER M., STREMMEL W. (2002). Relevance of underlying disease and bacterial vacA and cagA status on the efficacy of Helicobacter pylori eradication. Digestion. 65, 11-15. (Pubitemid 34310038)
14. SUERBAUM S., MICHETTI P. (2002). Helicobacter pylori infection. New Engl. J. Med. 347, 1175-1186.
15. SUGIMOTO M., YAMAOKA Y. (2009) Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch. Immunol. Ther. Exp. 57, 45-56.
16. SUGIMOTO M., FURUTA T., SHIRAI N., KODAIRA C., NISHINO M., YAMADE M., IKUMA M., WATANABE H., OHASHI K., HISHIDA A., ISHIZAKI T. (2007). Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin. Pharmacother. 8, 2701-2717. (Pubitemid 350193712)
17. TOVEY F. I., HOBSLEY M., HOLTON J. (2006). Helicobacter pylori virulence factors in duodenal ulceration: A primary cause or a secondary infection causing chronicity. World J. Gastroenterol. 12, 6-9. (Pubitemid 43126075)
18. VAKIL N., MÉGRAUD F. (2007). Eradication treatment for Helicobacter pylori. Gastroenterology. 133, 985-1001.
19. WANG M., FURUTA T., TAKASHIMA M., FUTAMI H., SHIRAI N., HANAI H., KANEKO E. (1999). Relation between interleukin-1beta messenger RNA in gastric fundic mucosa and gastric juice pH in patients infected with Helicobacter pylori. J. Gastroenterol. 34, 10-17. (Pubitemid 30072480)
20. YAKOOB J., JAFRI W., ABBAS Z., ABID S., NAZ S., KHAN R., KHALID A. (2011). Risk factors associated with Helicobacter pylori infection treatment failure in a high prevalence area. Epidemiol. Infect. 13, 581-590.
21. ZHAO J. J., WANG B. J., YANG L., LI Y. (2007). Influence of Helicobacter pylori genotype on triple eradication therapy. J. Gastroenterol. Hepatol. 22, 2251-2255. (Pubitemid 350145625)